Pharmacogenetics of antiarrhythmic therapy

Bibliography

• GARROD AE: Inborn Errors of Metabolism. Frowde and Stoughton, London, UK (1923).
   Google Scholar
• Pharmacogenetics – Heredity and Responses to Drugs. W Kalow (Ed.), Saunders, Philadelphia, PA, USA (1962).
   Google Scholar
• FORBAT A, LOND MB, LEHAMANN H, SILK E: Prolonged apnea following injection of succinylcholine. Lancet (1953) 2:1067-1068.
   Web of Science ®Google Scholar
• PRICE-EVAN DA, MANLEY FA, MCKUSICK VA: Genetic control of isoniazid metabolism in man. Br. Med. J. (1960) 2:485-491.
   PubMedGoogle Scholar
• WOOSLEY RL, DRAYER DE, REIDENBERG MM et al.: Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N. Engl. J. Med. (1978) 298:1157-1159.
   PubMed Web of Science ®Google Scholar
• MAHGOUB A, IDLE JR, DRING LG, LANCASTER R, SMITH RL: Polymorphic hydroxylation of debrisoquine in man. Lancet (1977) 2:584-586.
   PubMed Web of Science ®Google Scholar
• EICHELBAUM M, SPANNBRUCKER N, STEINCKE B, DENGLER HJ: Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur. J. Clin. Pharmacol. (1979) 16:183-187.
   PubMed Web of Science ®Google Scholar
• MEYER UA, ZANGER UM: Molecular mechanisms of genetic polymorphisms of drug metabolism. Ann. Rev. Pharmacol. Toxicol. (1997) 37:269-296.
   PubMed Web of Science ®Google Scholar
• DAHL ML, JOHANSSON I, BERTILSSON L, INGELMAN-SUNDBERG M, SJOQVIST F: Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. (1995) 274:516-520.
   PubMed Web of Science ®Google Scholar
• ROSES AD: Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev .Genet. (2004) 5:645-656.
   PubMed Web of Science ®Google Scholar
• EVANS WE, RELLING MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 286:487-491.
   PubMed Web of Science ®Google Scholar
• SACHIDANANDAM R, WEISSMAN D, SCHMIDT et al.: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature (2001) 409:928-933.
   PubMed Web of Science ®Google Scholar
• EVERS J, EICHELBAUM M, KROEMER HK: Unpredictability of flecainide plasma concentrations in patients with renal failure: relationship to side effects and sudden death? Ther. Drug Monit. (1994) 16:349-351.
   PubMed Web of Science ®Google Scholar
• BACHMANN KA: Genotyping and phenotyping the cytochrome P450 enzymes. Am. J. Ther. (2002) 9:309-316.
   PubMedGoogle Scholar
• LEE JT, KROEMER HK, SILBERSTEIN DJ et al.: The role of genetically determined polymorphic drug metabolism in the β-blockade produced by propafenone. N. Engl. J. Med. (1990) 322:1764-8.
   PubMed Web of Science ®Google Scholar
• HIGASHI MK, VEENSTRA DL, KONDO LM et al.: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 287:1690-1698.
   PubMed Web of Science ®Google Scholar
• WILKINSON GR: Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: some answers but still questions. Clin. Pharmacol. Ther. (2004) 76:99-103.
   PubMed Web of Science ®Google Scholar
• RODEN DM: Drug-induced prolongation of the QT interval. N. Engl. J. Med. (2004) 350:1013-1022.
   PubMed Web of Science ®Google Scholar
• FRETLAND AJ, LEFF MA, DOLL MA, HEIN DW: Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics (2001) 11:207-215.
   PubMedGoogle Scholar
• GRANT DM, HUGHES NC, JANEZIC SA et al.: Human acetyltransferase polymorphisms. Mutat. Res. (1997) 376:61-70.
   PubMed Web of Science ®Google Scholar
• GERLOFF T: Impact of genetic polymorphisms in transmembrane carrier-systems on drug and xenobiotic distribution. Naunyn Schmiedebergs Arch. Pharmacol. (2004) 369:69-77.
   PubMed Web of Science ®Google Scholar
• HOFFMEYER S, BURK O, VON RICHTER O et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA (2000) 97:3473-3478.
   PubMed Web of Science ®Google Scholar
• VERSTUYFT C, SCHWAB M, SCHAEFFELER E et al.: Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur. J. Clin. Pharmacol. (2003) 58:809-812.
   PubMed Web of Science ®Google Scholar
• KIM RB: Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab. Rev. (2002) 34:47-54.
   PubMed Web of Science ®Google Scholar
• FROMM MF, KIM RB, STEIN CM, WILKINSON GR, RODEN DM: Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation (1999) 99(4):552-557.
   PubMed Web of Science ®Google Scholar
• RODEN DM: Acquired long QT syndromes and the risk of proarrhythmia. J. Cardiovasc. Electrophysiol. (2000) 11:938-940.
   PubMed Web of Science ®Google Scholar
• SESTI F, ABBOTT GW, WEI J et al.: A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc. Natl. Acad. Sci. USA (2000) 97:10613-10618.
   PubMed Web of Science ®Google Scholar
• DONGER C, DENJOY I, BERTHET M et al.: KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation (1997) 96:2778-2781.
   PubMed Web of Science ®Google Scholar
• NAPOLITANO C, SCHWARTZ PJ, BROWN AM et al.: Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J. Cardiovasc. Electrophysiol. (2000) 11:691-696.
   PubMed Web of Science ®Google Scholar
• YANG P, KANKI H, DROLET B et al.: Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation (2002) 105:1943-1948.
   PubMed Web of Science ®Google Scholar
• PRIORI SG, NAPOLITANO C, MEMMI M et al.: Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation (2002) 106:69-74.
   PubMed Web of Science ®Google Scholar
• POSTMA AV, DENJOY I, HOORNTJE TM et al.: Absence of calsequestrin 2 causes severe forms of catecholaminergic polymorphic ventricular tachycardia. Circ. Res. (2002) 91:e21-e26.
   PubMed Web of Science ®Google Scholar
• MOHLER PJ, SCHOTT JJ, GRAMOLINI AO et al.: Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature (2003) 421:634-639.
   PubMed Web of Science ®Google Scholar
• RODEN DM: Taking the "idio" out of "idiosyncratic": predicting torsades de pointes. Pacing Clin. Electrophysiol. (1998) 21:1029-1034.
   PubMed Web of Science ®Google Scholar
• HOULTZ B, DARPO B, EDVARDSSON N et al.: Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation and flutter. Pacing Clin. Electrophysiol. (1998) 21:1044-1057.
   PubMed Web of Science ®Google Scholar
• CHOY AM, DARBAR D, DELL'ORTO S, RODEN DM: Exaggerated QT prolongation after cardioversion of atrial fibrillation. J. Am. Coll. Cardiol. (1999) 34:396-3401.
   PubMed Web of Science ®Google Scholar
• YANG T, SNYDERS DJ, RODEN DM: Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. Circ. Res. (1997) 80:782-789.
   PubMed Web of Science ®Google Scholar
• PAULUSSEN AD, GILISSEN RA, ARMSTRONG M et al.: Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J. Mol. Med. (2004) 82:182-188.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ PJ, PRIORI SG, NAPOLITANO C: How really rare are rare diseases? The intriguing case of independent compound mutations in the long QT syndrome. J. Cardiovasc. Electrophysiol. (2003) 14:1120-1121.
   PubMed Web of Science ®Google Scholar
• SPLAWSKI I, TIMOTHY KW, TATEYAMA M et al.: Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science (2002) 297:1333-1336.
   PubMed Web of Science ®Google Scholar
• CHEN S, CHUNG MK, MARTIN D et al.: SNP S1103Y in the cardiac sodium channel gene SCN5A is associated with cardiac arrhythmias and sudden death in a white family. J. Med. Genet. (2002) 39:913-915.
   PubMed Web of Science ®Google Scholar
• WEI J, WANG DW, ALINGS M et al.: Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. Circulation (1999) 99:3165-3171.
   PubMed Web of Science ®Google Scholar
• THE CARDIAC ARRHYTHMIA SUPPRESSION TRIAL (CAST) INVESTIGATORS: Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N. Engl. J. Med. (1989) 321:406-412.
   PubMed Web of Science ®Google Scholar
• BRUGADA R, BRUGADA J, ANTZELEVITCH C et al.: Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation (2000) 101:510-515.
   PubMed Web of Science ®Google Scholar
• MAKIELSKI JC, YE B, VALDIVIA CR et al.: A ubiquitous splice variant and a common polymorphism affect heterologous expression of recombinant human SCN5A heart sodium channels. Circ. Res. (2003) 93:821-828.
   PubMed Web of Science ®Google Scholar
• GROENEWEGEN WA, FIROUZI M, BEZZINA CR et al.: A cardiac sodium channel mutation cosegregates with a rare connexin40 genotype in familial atrial standstill. Circ. Res. (2003) 92:14-22.
   PubMed Web of Science ®Google Scholar